Figure 6.
Effects of AMD3100 treatment on peripheral immune cell populations after transient middle cerebral artery occlusion. Effect of AMD3100 treatment on CD3+, CD3+/CD4+, CD3+/CD8+, CD45R+, CD11b+, and CD11c+ cells in the spleen, blood, and thymus 6 days after tMCAO or sham operation. Values are presented as the median with the 25th to 75th percentiles and 95% confidence interval.